Thymidine can be added to antiviral therapy for chronic hepatitis B patients. Antiviral treatment for chronic hepatitis B patients generally uses first-line drugs such as entecavir and tenofovir, and these antiviral drugs can be taken together with thymopentin. Thymopeptide is a kind of immunomodulatory drug, which has the function of regulating and enhancing the body’s cellular immune function, and can be used to assist in the treatment of severe hepatitis and chronic active hepatitis. The common adverse effects of Thymopeptide include nausea, fever, dizziness, chest tightness and weakness, etc. Thymopeptide is contraindicated in patients who are allergic to Thymopeptide and in patients under 18 years old. The use of thymopentin also carries certain risks, and should be used under the guidance of a specialist to avoid adverse effects.